Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01551329 · ClinicalTrials.gov registry record · Phase 1
Ketamine for Depression and Alcohol Dependence
A Phase 1 study, sponsored by Yale University.
- Completed
- Registry status
- Phase 1
- Development phase
- 5
- Enrollment target
NCT01551329 is a Phase 1 study that has completed, run by Yale University. The registered enrollment target is 5 participants.
The verdict
NCT01551329, a Phase 1 study, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 5 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy of ketamine in reducing depressive symptoms in subjects with a comorbid major depressive episode and alcohol dependence. The investigators hypothesize the following for the present study: A single dose of ketamine will induce a rapid, robust and sustained reduction in depressive symptoms in subjects with a comorbid major depressive episode and alcohol dependence relative to placebo as defined by change in Hamilton Depression Rating Scale total scores at 72 hours post infusion. A single dose of ketamine can be delivered safely, with minimal adverse events or complications, in subjects with a comorbid major depressive episode and alcohol dependence.
Interventions
- DRUG Ketalar (ketamine)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2012-03 |
| Est. Completion | 2015-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01551329
The ClinicalTrials.gov registry entry for NCT01551329 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Ketalar (ketamine) is the first listed.
NCT01551329 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01551329 about?
NCT01551329 is a clinical study titled "Ketamine for Depression and Alcohol Dependence". The purpose of this study is to evaluate the efficacy of ketamine in reducing depressive symptoms in subjects with a comorbid major depressive episode and alcohol dependence. The investigators hypothesize the following for the present study: A single dose of ketamine will induce a rapid, robust and...
What is the current status of trial NCT01551329?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 5 participants. The study started on 2012-03. Estimated completion is 2015-11.
What interventions are being tested in trial NCT01551329?
The interventions under investigation include: Ketalar (ketamine) (DRUG).
Who is sponsoring clinical trial NCT01551329?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.